Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number three in sales among the world-wide industry.[when?] Company sales totalled 36.173 billon US$ in 2008. Currently,[when?] Novartis is the sixth largest pharmaceutical company in terms of revenue ($41.5 billion in 2009) with a profit margin of about 20%, which is the same as its industry competitors. Novartis profits were down by 31% from 2007 levels. Novartis manufactures such drugs as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate and (Gleevec / Glivec). Additional agents include ciclosporin (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. Renamed to Novartis following an acquisition by Ciba-Geigy, it owns Sandoz, a large manufacturer of generic drugs. The company formerly owned the Gerber Products Company, a major infant and baby products producer, but sold it to Nestlé on 1 September 2007.
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
Latest FEC Datacovers through committee's December 31, 2008 filing.
Summaryoverview of the committee's finances
- Total Raised:
- Total Spent:
- Cash on Hand:
Standardized Donation Informationcovers roughly through Q4 2012. may lag behind FEC section above, as donors and industries are identified by hand.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Novartis Corp
Names of Lobbyists
Firm Hired Amount Novartis Corp $11,474,420 Ruder Finn Inc $20,000 Keaney Consulting $0
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Fed Budget & Appropriations,
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Government Issues,
Most Frequently Disclosed Bills
Bill No. Title H.R.1908 Patent Reform Act of 2007 S.1145 Patent Reform Act of 2007 S.1695 Biologics Price Competition and Innovation Act of 2007 H.R.1956 Patient Protection and Innovative Biologic Medicines Act of 2007 S.1505 Affordable Biologics for Consumers Act S.3678 Vietnam Human Rights Act of 2008 H.R.1038 H.R.4703 Vaccine Shortage Preparedness Act of 2008 S.2029 Physician Payments Sunshine Act of 2007 H.R.4991 Vaccine Shortage Preparedness Act of 2008
RegulationsMentioned in 4 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Novartis Corp" in public comments on proposed federal regulations.
Mentions in Document Text
View all mentions data for Novartis Corp
- Toggle 5 FDA Patent Extension Application for TEKTURNA (Aliskiren hemifumarate), U.S. Patent No. 5,559,111 2007
- Toggle 3 FDA Patent Term Extension Application for EXELON PATCH (rivastigmine), U.S. Patent No. 5,602,176 2008
- Toggle 1 EPA Greenhouse Gas Mandatory Reporting 2008
- Toggle 1 EPA Diazinon, Dicrotophos, Fluometuron, Fluvalinate, Napropamide, Piperonyl Butoxide, Propazine, and Pyrazon; Proposed Tolerance Actions 2007
EPA Violations2 Enforcement Actions
Figures are based on data from the Environmental Protection Agency’s ECHO website. The ECHO database contains federal and state environmental enforcement actions. Data displayed here includes only those actions that began after 2000 and resulted in fines of over $1 million.
Actions where the company was the sole defendant are listed first. Actions where the company is one of multiple defendants are listed subsequently.
For more information see our EPA methodology page.
|Agere Systems, Et Al||Novartis Corporation (+138 others)||2007||Elkton, Md||$11,300,000|
|Advanced Environmental Technology Corp.||Novartis Pharmaceuticals Corp. (+13 others)||2007||Sayreville Boro, Nj; ...||$9,863,579|